STOCK TITAN
  1. Home
  2. News
  3. MGTX

MeiraGTx Holdings plc - MGTX STOCK NEWS

Welcome to our dedicated news page for MeiraGTx Holdings plc (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on MeiraGTx Holdings plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MeiraGTx Holdings plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MeiraGTx Holdings plc's position in the market.

News
MeiraGTx to Participate in Upcoming Investor Conferences
Rhea-AI Summary
MeiraGTx Holdings plc (NASDAQ: MGTX) announced its participation in upcoming investor conferences. Alexandria Forbes, Ph.D., President, and CEO will present at Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, BofA Securities Healthcare Conference 2024, and Goldman Sachs 45th Annual Global Healthcare Conference. Live webcasts will be available on the Investors page of the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
conferences
-
News
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
Rhea-AI Summary
MeiraGTx gave an oral presentation at the American Academy of Oral Medicine Annual Conference on a Phase 1 study of gene therapy for radiation-induced xerostomia. The study showed significant improvements in patient-reported outcomes and saliva flow rates, indicating the treatment's effectiveness and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
none
-
News
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
Rhea-AI Summary
MeiraGTx Holdings plc (MGTX) announces financial results and operational updates, including progress in clinical programs for radiation-induced xerostomia, retinal diseases, and Parkinson's disease. The company aligns with FDA for Phase 2 AQUAx2 trial, presents positive data at AAOM, and enters agreements with Janssen and Sanofi. MeiraGTx also reports successful treatment outcomes for LCA4 patients and advancements in riboswitch gene regulation technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.09%
Tags
earnings
News
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
Rhea-AI Summary
MeiraGTx receives $50 million milestone for Phase 3 LUMEOS trial extension study for XLRP treatment. Anticipates further milestone payments and revenue from commercial sales and manufacturing agreement with J&J.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.55%
Tags
none
-
News
Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors
Rhea-AI Summary
Sanofi makes a strategic equity investment in Graviton Bioscience, granting a 12-month right of first negotiation to explore collaboration opportunities across various indications, including immunological and metabolic syndrome indications. Graviton Bioscience is focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) and other therapeutic compounds. The investment aims to drive the momentum behind ROCK2 inhibitor treatments, which are implicated in the pathology of metabolic, autoimmune, inflammatory, and neurologic disorders with inadequate or no treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
-
News
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
Rhea-AI Summary
MeiraGTx Holdings plc (Nasdaq: MGTX) enters into an Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. for the treatment of X-linked retinitis pigmentosa (XLRP) related to botaretigene sparoparvovec (bota-vec), securing up to $415 million. The agreement includes $130 million in upfront and near-term milestone payments, with potential additional revenue from commercial sales and manufacturing technology transfer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.59%
Tags
none
News
MeiraGTx to Participate in Upcoming Investor Conferences
Rhea-AI Summary
MeiraGTx Holdings plc (MGTX) announced the participation of its President and CEO, Dr. Alexandria Forbes, in two upcoming investor conferences. The live webcasts of the corporate presentations will be available on the Investors page of the company’s website, with replays accessible for approximately 30 days following the presentation dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
conferences
-
News
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
Rhea-AI Summary
MeiraGTx Holdings plc (Nasdaq: MGTX) announced a strategic investment from Sanofi, purchasing $30 million of ordinary shares at $7.50 per share. They also announced a right of first negotiation (ROFN) with Sanofi for the use of MeiraGTx’s Riboswitch gene regulation technology for certain CNS and I&I targets, including IL-4 and IL-13, as well as for GLP-1 and other gut peptides for metabolic disease. Enrollment in the Phase 2 study of AAV2-hAQP1 for the treatment of RIX is ongoing. The company presented eight posters at the ESGCT 2023 Annual Congress and received a 2nd Commercial Manufacturer’s/Importer’s Authorization (MIA) for QC testing at their manufacturing facility in Shannon, Ireland.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
earnings
-
News
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
Rhea-AI Summary
MeiraGTx Holdings plc announced that Sanofi has made a $30 million strategic investment in the company. Sanofi will purchase 4.0 million ordinary shares at a price of $7.50 per share. Sanofi will also receive a right of first negotiation for the use of MeiraGTx's Riboswitch gene regulation technology for certain Immunology and Inflammation and Central Nervous System targets, as well as for metabolic disease. MeiraGTx is actively pursuing strategic options with other interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.27%
Tags
none
News
MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
Rhea-AI Summary
MeiraGTx to exhibit eight posters and deliver one oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress. The presentations highlight the depth of innovation in MeiraGTx's technology platforms for gene and cell therapy, particularly in the areas of riboswitch and neurodegenerative programs. The company looks forward to sharing data on its innovative pipeline, manufacturing, and R&D capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
Stock MGTX logo
MeiraGTx Holdings plc

Nasdaq:MGTX

MGTX Rankings

#3393 Ranked by Market Cap
#4643 Ranked by Stock Gains
N/A Ranked by Dividends

MGTX Stock Data

357.05M
25.72M
17.51%
62.22%
1.78%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
New York

About MGTX

meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.